Results 241 to 250 of about 14,212 (288)

Neurophysiological effects of botulinum toxin type a

Neurotoxicity Research, 2006
Botulinum toxin type A (BoNT-A) acts peripherally by inhibiting acetylcholine release from the presynaptic neuromuscular terminals, thus weakening muscle contraction, and its clinical benefit depends primarily on the toxin's peripheral action. In addition to acting directly at the neuromuscular junction, the toxin alters sensory inputs to the central ...
ABBRUZZESE, GIOVANNI, BERARDELLI A.
openaire   +3 more sources

Botulinum toxin type A for facial wrinkles

Cochrane Database of Systematic Reviews, 2021
Botulinum toxin type A (BontA) is the most frequent treatment for facial wrinkles, but its effectiveness and safety have not previously been assessed in a Cochrane Review.To assess the effects of all commercially available botulinum toxin type A products for the treatment of any type of facial wrinkles.We searched the following databases up to May 2020:
Cristina Pires, Camargo, Jun, Xia, Caroline S, Costa, Rolf, Gemperli, Maria Dc, Tatini, Max K, Bulsara, Rachel, Riera   +6 more
openaire   +2 more sources

Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A

Dermatologic Surgery, 2003
Botulinum toxin type B (BTX-B; Myobloc) has recently been introduced for the treatment of dynamic rhytides. This serotype is structurally similar to botulinum toxin type A (BTX-A; Botox) and appears to produce equivalent muscular paralysis. Because of the fact that some patients may become resistant to the effects of BTX-A with its continued use or may
Tina S, Alster, Jason R, Lupton
openaire   +2 more sources

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Movement Disorders, 2002
AbstractIn some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop.
Dirk, Dressler, Hans, Bigalke
openaire   +2 more sources

Botulinum toxin type E: A review

Dermatological Reviews, 2022
AbstractBackgroundBotulinum toxin type A (BoNT‐A) and botulinum toxin type B are the only two serotypes of botulinum toxin currently available for therapeutic use. Recently, botulinum toxin type E (BoNT‐E) has been explored for clinical use due to its pharmacological properties.
Emily Lebowitz, Diane Berson
openaire   +1 more source

Studies using Clostridium botulinum toxin—Type A

Toxicology and Applied Pharmacology, 1965
Abstract Several drugs and ions were given to white mice injected with Clostridium botulinum type A toxin in an attempt to prolong survival time in these mice. Agents used included choline, barbital, chlorpromazine, Thio-TEPA, CaCl 2 , and MgCl 2 . Only choline had a significant effect, and its effect was to shorten survival time.
L G, HART, R L, DIXON, J P, LONG, B, MACKAY   +3 more
openaire   +2 more sources

Botulinum toxin type A therapy during pregnancy

Movement Disorders, 2004
AbstractInjection with botulinum toxin type A (Botox) is a safe and efficacious treatment for idiopathic cervical dystonia. We present the first case report of clinical Botox treatment during pregnancy. This patient underwent four apparently uncomplicated full‐term pregnancies while receiving regular Botox treatments.
William J, Newman, Thomas L, Davis, Bimal B, Padaliya, Bismal B, Padaliya, Cassondra D, Covington, Chandler E, Gill, Anna I, Abramovitch, P David, Charles   +7 more
openaire   +2 more sources

Molecular Weight of Type A Botulinum Toxin

Infection and Immunity, 1970
Clostridium botulinum type A does not produce a 12,000 molecular weight toxin. The reported isolation of such a material by Gerwing et al. could not be confirmed.
J N, Knox, W P, Brown, L, Spero
openaire   +2 more sources

Purification of Clostridium botulinum type a toxin

Biochimica et Biophysica Acta (BBA) - Protein Structure, 1970
Abstract The neurotoxin of Clostridium botulinum Type A has been isolated and purified from a liquid culture. The toxin is homogeneuous by anion and cation exchange chromatography, gel filtration, isoelectric focusing and Ouchterlony gel diffusion technique. The specific toxicity of the purified toxin is 10 · 107 minimum lethal doses/1.0 A 278
B R, Dasgupta, L J, Berry, D A, Boroff
openaire   +2 more sources

Detoxification of Crystalline Botulinum Type A Toxin

The Journal of Immunology, 1947
Summary Botulinum Type A toxoid has been prepared from crystalline toxin by the addition of formaldehyde. The most active preparation consisted of one component electrophoretically, immunized mice in a dose containing 0.01γ of toxoidnitrogen and was 2400 times more active antigenically than crude toxoid on the basis of nitrogen-content.
G A, HOTTLE, A, ABRAMS
openaire   +2 more sources